Intensification of Chemotherapy for Myeloid Blast Phase CML
Author Information
Author(s): Lee Benjamin J., Griffin Shawn P., Doh Jean, Ciurea Stefan O., Jeyakumar Deepa, Kongtim Piyanuch, Naqvi Kiran
Primary Institution: University of California Irvine Health
Hypothesis
Does a three-drug timed-sequenced regimen improve outcomes compared to standard chemotherapy in patients with myeloid blast phase CML?
Conclusion
Intensification of upfront chemotherapy does not appear to improve treatment outcomes in patients with myeloid blast phase CML.
Supporting Evidence
- 50% of patients received a timed-sequenced regimen and 50% received standard chemotherapy.
- Hematologic response was similar between both treatment groups at 55.6%.
- 66.7% of patients experienced at least one grade ≥ 3 non-hematologic toxicity.
- Overall survival was not significantly different between treatment groups.
Takeaway
This study looked at patients with a type of leukemia and found that using stronger chemotherapy didn't help them get better compared to a standard treatment.
Methodology
Retrospective evaluation of newly diagnosed CML-MBP patients treated with either a timed-sequenced regimen or standard chemotherapy.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
Single-center, retrospective design with a small sample size.
Participant Demographics
Median age was 51 years, with 61.1% male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website